Allergy shots are commonly used to treat children with severe environmental allergies and asthma, but under-the-tongue drops may offer yet another beneficial – and stick-free – option for pediatric allergy sufferers, according to a Johns Hopkins Children’s Center review of existing scientific evidence.
The new research comes on the heels of another recent Hopkins study, which showed that oral drops provide a safe and effective alternative for adult allergy sufferers.
The new review, is an analysis of 34 previously published clinical trials and suggests that both drops and injections work well in alleviating the bothersome symptoms of allergic rhinitis and asthma, the research team says. In addition to being better tolerated by needle-averse children, the oral treatment can be given at home, sparing the family a visit to the doctor’s office.
‘Our findings suggest the needle-free approach is a reasonable way to provide much needed relief to millions of children who suffer from asthma or seasonal allergies,’ says lead author Julia Kim, M.D., M.P.H., a pediatric research fellow at Johns Hopkins Children’s Center.
Allergy shots, which contain tiny amounts of proteins found in environmental allergens such as dust mites and pollen, are a standard treatment for severe seasonal allergies in children who do not get relief from medication. However, under-the-tongue drops are not approved for use by the U.S. Food and Drug Administration and are only offered off label by some physicians. The needle-free approach, however, is widely available in Europe, where patients are commonly treated with sublingual pills and drops, the researchers say.
The findings, Kim notes, are encouraging enough to prompt a second look at oral drops as a treatment option.
The Hopkins researchers first looked at 13 studies that involved 920 children and compared the efficacy of allergy injections to either placebo or standard allergy medication. Overall, the researchers found that injections provide better symptom relief than placebo and standard medication for children with asthma or allergic rhinitis. The team next analyzed 18 trials involving 1,580 children treated with oral-drop therapy, placebo or standard medication for asthma and rhinitis or either condition alone. In this group, the researchers also found that oral drops provided superior relief of asthma symptoms, compared with patients who got the placebo and/or standard drugs. Oral drops also provided better symptom relief than placebo or standard medication in children with allergic rhinitis or rhino-conjunctivitis, a condition marked by runny nose and itchy, red and swollen eyes.
Only three of the 34 studies in the review directly compared shots and drops and, the investigators say, more head-to-head comparisons may shed better light on the comparative effectiveness of the two treatments. However, the researchers add, the results of the 31 remaining studies they looked at indicate both oral drops and allergy shots can successfully rid children of coughing, sneezing, runny noses, itchy eyes and wheezing.
The three studies that directly compared injections versus oral drops for symptom relief of dust mite-induced asthma and rhinitis showed no strong evidence that children given shots fared better than children who got oral drops, Kim said.
Both treatments, overall, caused relatively mild side effects, such as itching of the mouth, skin rashes or wheezing. A single severe reaction was reported following an injection. Johns Hopkins Children

Strokes occur when a brain clot blocks blood flow in parts of the brain, essentially starving groups of neurons of oxygen, which is necessary for normal function. Nearly 130,000 of the 795,000 strokes Americans suffer annually result in death, accounting for roughly 5% of deaths in the U.S. The remaining 665,000 stroke patients suffer a wide variety of side effects ranging from complete loss of motor function to loss of speech to a catatonic state. Because of the horrific nature of these cerebrovascular events and their consequences, many clinical researchers focus on prevention, rehabilitation and restoration of function for stroke victims.

A technique developed through these efforts utilises transcranial magnetic stimulation (TMS) to improve language function in stroke patients with chronic aphasia. Patients who have undergone this procedure have previously reached a plateau in their ability to produce fluent language, despite signs of understanding and frustration at their inability to communicate.

‘The heart of our work is to use non-invasive brain stimulation

Surgeons at University Hospitals Case Medical Center, Cleveland, are working to reduce serious complications that have been known to occur with colorectal operations. In addition to using a set of pre-and postoperative standards that speed recovery which they have been publishing on for more than a decade, the researchers have validated yet another step surgeons can take to further reduce patients

Discovering that mouse hair has a circadian clock – a 24-hour cycle of growth followed by restorative repair – researchers suspect that hair loss in humans from toxic cancer radiotherapy and chemotherapy might be minimised if these treatments are given late in the day.
The study found that mice lost 85 percent of their hair if they received radiation therapy in the morning, compared to a 17 percent loss when treatment occurred in the evening.
The researchers, from Salk Institute for Biological Studies, the University of Southern California (USC) and the University of California, Irvine (UCI), worked out the precise timing of the hair circadian clock, and also uncovered the biology behind the clockwork – the molecules that tells hair when to grow and when to repair damage. They then tested the clock using radiotherapy.
‘These findings are particularly exciting because they present a significant step towards developing new radiation therapy protocols that include minimising negative side effects on normal tissues, such as hair or bone marrow, while maintaining the desired effects on cancer cells,’ says Maksim Plikus, assistant professor of developmental and cell biology at UCI and the study’s first author. ‘We will now apply our findings to design novel circadian rhythm-based approaches to cancer therapy.’
The scientists can’t say their findings will directly translate to human cancer therapy because they haven’t yet studied that possibility. But they say it is becoming increasingly clear that body organs and tissues have their own circadian clocks that, when understood, could be used to time drug therapy for maximum benefit.
‘There are clocks everywhere in the body – clocks that have their own unique rhythm that, we found, have little to do with the central clock in our brains,’ says the study’s co-lead investigator, Satchidananda Panda, an associate professor in Salk’s Regulatory Biology Laboratory and an expert on circadian rhythm.
‘This suggests that delivering a drug to an organ while it is largely inactive is not a good idea. You could do more damage to the organ than when it is awake, repairing and restoring itself,’ says Panda. ‘If you know when an organ is mending itself, you might be able to deliver more potent doses of a drug or therapy. That might offer a better outcome while minimising side effects.’ Salk Institute for Biological Studies